Developer docs
API playgroundTry for free, no card

Search company profiles

Genezen

Full company profile

uuid0000wnk

Namestring
Genezen
Legal namestring
Genezen Laboratories, Inc.
Websiteurl
genezen.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Genezen is a privately held contract development and manufacturing organization (CDMO) specializing in viral vector production for gene and cell therapy developers. Founded in 2014 in Indianapolis by Bill Vincent, the company operates from two U.S. facilities: a 60,000 ft² cGMP multi-vector production site in Fishers, Indiana (originally completed in 2022) and an 86,000 ft² commercial gene therapy manufacturing facility in Lexington, Massachusetts acquired from uniQure in 2024. Services span end-to-end lentiviral, retroviral, and adeno-associated virus (AAV) vector manufacturing, plasmid design, cell therapy manufacturing, analytical development and testing, and a discovery-stage offering branded Propel: Discovery.

The company's technical platform rests on a licensed exclusive agreement with CSL for the Cytegrity™ stable lentivirus production system (with demonstrated functional titers up to 1e7 TU/mL), proprietary suspension HEK293T cell lines and synthetic DNA workflows, and fixed-bed bioreactor systems enabling scalable production with reduced batch-to-batch variability. Genezen supports FDA and EMA-compliant GMP production and has demonstrated regulatory readiness through late-stage and pivotal clinical supply partnerships.

Genezen generates revenue through fee-for-service CDMO contracts with biotech and pharmaceutical companies developing gene and cell therapies. The customer base spans gene therapy developers, cell therapy companies, rare disease foundations, and academic research institutions, including named engagements with Atsena Therapeutics (commercial manufacturing partnership targeting 2028 BLA), Seattle Children's Research Institute, Optieum Biotechnologies, Humane Genomics, The Charlotte & Gwenyth Gray Foundation, and Elly's Team. Go-to-market is executed through direct enterprise sales, industry conferences (ASGCT, BIO International, MassBio), and academic partnerships; pricing is quote-based and not publicly disclosed. The company is majority-backed by Ampersand Capital Partners following an $18.5 million growth equity investment in November 2023.

Short descriptiontext

Genezen is a U.S.-based CDMO providing lentiviral, retroviral, and AAV viral vector manufacturing, cell therapy services, and analytical testing for gene and cell therapy developers across two cGMP facilities in Indiana and Massachusetts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
viral vector manufacturing, cell therapy CDMO, gene therapy services, GMP biopharmaceutical manufacturing, lentiviral vector production
Industry5 codes
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Viral Vector and Cell Therapy Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CDMO Manufacturing Services
TypeProfessional Services
Description

Fee-for-service contract development and manufacturing organization providing viral vector manufacturing, process development, analytical testing, and cell therapy services to biotech and pharma companies on a project basis.

genezen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genezen is a contract development and manufacturing organization (CDMO) providing end-to-end viral vector and cell therapy manufacturing services for gene therapy developers. Its offering spans lentiviral, retroviral, adeno-associated virus (AAV), plasmid, and cell therapy manufacturing supported by analytical development and testing services, delivered across two cGMP-compliant facilities in Fishers, Indiana and Lexington, Massachusetts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Demonstrated functional titers of up to 1e7 TU/mL using Cytegrity™ system
+2 more records
Product overview1 text field

Genezen is a contract development and manufacturing organization (CDMO) providing a comprehensive suite of viral vector and cell therapy manufacturing services. The core offering comprises Lentiviral Vector CDMO Services, Retroviral Vector CDMO Services, Adeno-Associated Viral Vector CDMO Services, Cell Therapy CDMO Services, and Plasmids Manufacturing, supported by Analytical Development and Testing Services. The company also offers Propel: Discovery for early-stage programs. Genezen's manufacturing is powered by proprietary technology platforms including the Cytegrity Stable Lentivirus Production System and Fixed-Bed Bioreactor Manufacturing Platform. Services span from pre-clinical research through commercial-scale manufacturing across two facilities: a 60,000 ft2 development and manufacturing facility in Fishers, Indiana, and an 86,000 ft2 commercial-scale facility in Lexington, Massachusetts.

Product and service7 records
1Lentiviral Vector CDMO Services
CategoryViral Vector CDMO Services
Description

End-to-end lentiviral vector manufacturing services from plasmid design and cell line development through GMP production, supporting both adherent and suspension processes with single-use technology. Targeted at gene therapy developers requiring clinical and commercial-grade lentiviral vectors.

2Retroviral Vector CDMO Services
CategoryViral Vector CDMO Services
Description

Retroviral vector manufacturing services utilizing state-of-the-art facilities designed for aseptic manufacture, delivering larger batches with consistency and reliability. Designed for gene and cell therapy developers needing retroviral vector production.

3Cell Therapy CDMO Services
CategoryCell Therapy CDMO Services
Description

Cell therapy manufacturing services leveraging world-class partnerships to streamline production and advance cell therapies from trial through commercialization. Supports CAR-T and other cell therapy developers requiring integrated viral vector and cell therapy manufacturing.

4Plasmids Manufacturing
CategoryViral Vector CDMO Services
Description

Plasmid design and manufacturing services, utilizing preferred partners' proven platforms or working with client-provided plasmids to meet unique requirements. Supports gene therapy developers across the manufacturing lifecycle.

5Adeno-Associated Viral Vector CDMO Services
CategoryViral Vector CDMO Services
Description

AAV vector manufacturing services leveraging over a decade of experience with diverse platforms, processes, and analytics to advance programs from molecule to medicine. Targeted at gene therapy developers across preclinical, clinical, and commercial stages.

6Propel: Discovery
CategoryDiscovery & Early Development Services
Description

Discovery-stage support services designed to accelerate early development gene and cell therapy programs through Genezen's expertise and facilities. Targeted at developers in the earliest preclinical phases.

7Analytical Development and Testing Services
CategoryAnalytical & Quality Control Services
Description

Comprehensive testing services including potency assays (biological titers, vector genome titers, TCID50), identity testing (VCN, insert stability, genome integrity by NGS), stability testing, purity testing, residual testing, and safety testing (RCL/RCR assays, sterility, endotoxin, mycoplasma).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Expanded partnership to strengthen support for foundation-funded gene therapy programs, providing comprehensive testing and quality services for rare disease therapies.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Manufacturing partnership to advance CLN6 gene therapy into Phase 1/2 clinical trial for Batten disease. Genezen supported rapid progression from proof of concept to GMP clinical supply using its viral vector platform and regulatory expertise, including direct FDA engagement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Strategic commercial manufacturing partnership for clinical development and commercial manufacturing of Atsena's AAV gene therapy pipeline, including ATSN-201 for X-linked retinoschisis targeting BLA filing in early 2028. Genezen leverages its viral vector manufacturing expertise to provide a streamlined and cost-efficient path to commercial manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Manufacturing partnership supporting Atsena's pivotal LIGHTHOUSE study for XLRS treatment and advancing programs toward regulatory approval and commercial launch.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Partnership to develop and manufacture HGI627, an oncolytic viral therapy targeting pediatric liver cancer. Collaboration involves process transfer and cGMP manufacturing using Humane Genomics' proprietary RNA virus platform.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-05-25
Description

Partnership to support cGMP manufacturing of groundbreaking CAR-T therapy for glioblastoma, leveraging Genezen's viral vector and cell therapy manufacturing capabilities.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2025-05-13
Description

Partnership for AAV9 gene replacement therapy targeting NEDAMSS (Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures). Genezen provided CMC expertise for development of analytical/ancillary studies to support IND submission, and Dr. Susan D'Costa joined the foundation's board.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2024-03-06
Description

Strategic manufacturing partnership for X-linked agammaglobulinemia (XLA) cell therapy program. Licensing of proven stable producer system for lentiviral vector production provides clients access to cutting-edge technology for stable and scalable high-titer clinical lentivirus production.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-02-21
Description

Licensing agreement for Cytegrity™ proprietary stable lentivirus production system from CSL. This next-generation technology offers remarkable efficiency, streamlined and cost-effective solution, seamless scalability, and reduced batch-to-batch variability with demonstrated functional titers up to 1e7 TU/mL.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Research institution partnership providing access to the Indiana University Gene Therapy Testing Laboratory for clinical trial subject testing and release testing services, including RCL/RCR testing, PCR testing, insertion site analysis, and p24 ELISA.

Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2015-01-01
Description

Research partnership with Cincinnati Children's Hospital Medical Center Translational Core Laboratory providing access to expertise in transducing hematopoietic progenitors, stem cells, T lymphocytes, and other immune cells for cell therapy manufacturing services.

12Vanguard Clinical, Inc.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Vanguard Clinical for development support on CLN6 Batten disease program, with CEO Tiffany Sepp serving as Development Team Leader for the Gray Foundation.

genezen.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Columbus, OH-based viral vector CDMO offering lentiviral, AAV, and other viral vector manufacturing for gene therapy developers. Closely comparable to Genezen in multi-modality vector manufacturing, scale (similar facility footprint), and customer base (early- to mid-stage gene therapy developers).

TypeDirect peer
Description

Columbus, OH-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Direct competitor in the AAV CDMO space with overlapping customer segments (gene therapy biotechs from preclinical through commercial) and similar technology platform approach.

TypeDirect peer
Description

Spanish AAV CDMO owned by AskBio (acquired by Bayer), one of the largest dedicated viral vector manufacturers globally. Comparable to Genezen in AAV manufacturing focus, though at significantly larger scale and with European footprint advantage for global gene therapy sponsors.

4Yposkesi (SK pharmteco)
TypeDirect peer
Description

France-based lentiviral and AAV CDMO (formerly Yposkesi), now part of SK pharmteco. Highly comparable to Genezen in lentiviral vector manufacturing focus, multi-vector platform, and biotech client base; provides Genezen's main European-headquartered competition for viral vector programs.

TypeBroad incumbent
Description

Large-scale global CDMO with viral vector manufacturing services for cell and gene therapies. Comparable as an incumbent competitor offering broader CDMO services (biologics fill-finish, oral dose forms) plus gene therapy vector production, competing with Genezen for larger gene therapy manufacturing RFPs.

TypeBroad incumbent
Description

Global life sciences services platform that acquired Brammer Bio (viral vector CDMO). Competes with Genezen across the viral vector CDMO space with significantly greater scale, integrated services, and balance sheet, particularly for late-stage and commercial gene therapy programs.

TypeBroad incumbent
Description

Swiss global CDMO leader offering viral vector and cell therapy manufacturing services. Comparable to Genezen in viral vector and cell therapy manufacturing, but operating at substantially larger scale with broader biologics portfolio and global geographic footprint.

8AavantiBio
TypeEmerging player
Description

AAV-focused gene therapy CDMO spun out from the University of Florida. Compares to Genezen in AAV manufacturing focus and gene therapy developer client base, though operating at earlier commercial scale and narrower single-modality platform.

TypeBroad incumbent
Description

Biomanufacturing technology company offering viral vector, cell therapy, and biologics manufacturing services. Compares to Genezen in viral vector CDMO services, with broader biomanufacturing portfolio and significant capital backing from public and private sources.

TypeEmerging player
Description

Cell engineering technology company supporting cell therapy developers including GMP manufacturing support. Adjacent peer to Genezen's cell therapy CDMO offering, with overlapping customer base in CAR-T and other cell therapy developers requiring lentiviral vector supply.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genezen

Viral Vector and Cell Therapy Contract Manufacturing (CDMO)genezen.com

Genezen is a U.S.-based CDMO providing lentiviral, retroviral, and AAV viral vector manufacturing, cell therapy services, and analytical testing for gene and cell therapy developers across two cGMP facilities in Indiana and Massachusetts.

What Genezen does

Genezen is a privately held contract development and manufacturing organization (CDMO) specializing in viral vector production for gene and cell therapy developers. Founded in 2014 in Indianapolis by Bill Vincent, the company operates from two U.S. facilities: a 60,000 ft² cGMP multi-vector production site in Fishers, Indiana (originally completed in 2022) and an 86,000 ft² commercial gene therapy manufacturing facility in Lexington, Massachusetts acquired from uniQure in 2024. Services span end-to-end lentiviral, retroviral, and adeno-associated virus (AAV) vector manufacturing, plasmid design, cell therapy manufacturing, analytical development and testing, and a discovery-stage offering branded Propel: Discovery.

The company's technical platform rests on a licensed exclusive agreement with CSL for the Cytegrity™ stable lentivirus production system (with demonstrated functional titers up to 1e7 TU/mL), proprietary suspension HEK293T cell lines and synthetic DNA workflows, and fixed-bed bioreactor systems enabling scalable production with reduced batch-to-batch variability. Genezen supports FDA and EMA-compliant GMP production and has demonstrated regulatory readiness through late-stage and pivotal clinical supply partnerships.

Genezen generates revenue through fee-for-service CDMO contracts with biotech and pharmaceutical companies developing gene and cell therapies. The customer base spans gene therapy developers, cell therapy companies, rare disease foundations, and academic research institutions, including named engagements with Atsena Therapeutics (commercial manufacturing partnership targeting 2028 BLA), Seattle Children's Research Institute, Optieum Biotechnologies, Humane Genomics, The Charlotte & Gwenyth Gray Foundation, and Elly's Team. Go-to-market is executed through direct enterprise sales, industry conferences (ASGCT, BIO International, MassBio), and academic partnerships; pricing is quote-based and not publicly disclosed. The company is majority-backed by Ampersand Capital Partners following an $18.5 million growth equity investment in November 2023.

Genezen firmographics

Firmographics
Name
Genezen
Legal name
Genezen Laboratories, Inc.
Website
https://genezen.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
251–500 employees
Short description
Genezen is a U.S.-based CDMO providing lentiviral, retroviral, and AAV viral vector manufacturing, cell therapy services, and analytical testing for gene and cell therapy developers across two cGMP facilities in Indiana and Massachusetts.
Ownership category
akta.pro rank

Genezen industry classification

Industry
Product category
Viral Vector and Cell Therapy Contract Manufacturing (CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Viral vector manufacturing
  • Cell therapy CDMO
  • Gene therapy services
  • GMP biopharmaceutical manufacturing
  • Lentiviral vector production

Where Genezen is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Genezen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Manufacturing Services: Fee-for-service contract development and manufacturing organization providing viral vector manufacturing, process development, analytical testing, and cell therapy services to biotech and pharma companies on a project basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Genezen product offering

Product offering

Core offering

Genezen is a contract development and manufacturing organization (CDMO) providing end-to-end viral vector and cell therapy manufacturing services for gene therapy developers. Its offering spans lentiviral, retroviral, adeno-associated virus (AAV), plasmid, and cell therapy manufacturing supported by analytical development and testing services, delivered across two cGMP-compliant facilities in Fishers, Indiana and Lexington, Massachusetts.

Product overview

Genezen is a contract development and manufacturing organization (CDMO) providing a comprehensive suite of viral vector and cell therapy manufacturing services. The core offering comprises Lentiviral Vector CDMO Services, Retroviral Vector CDMO Services, Adeno-Associated Viral Vector CDMO Services, Cell Therapy CDMO Services, and Plasmids Manufacturing, supported by Analytical Development and Testing Services. The company also offers Propel: Discovery for early-stage programs. Genezen's manufacturing is powered by proprietary technology platforms including the Cytegrity Stable Lentivirus Production System and Fixed-Bed Bioreactor Manufacturing Platform. Services span from pre-clinical research through commercial-scale manufacturing across two facilities: a 60,000 ft2 development and manufacturing facility in Fishers, Indiana, and an 86,000 ft2 commercial-scale facility in Lexington, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lentiviral Vector CDMO Services End-to-end lentiviral vector manufacturing services from plasmid design and cell line development through GMP production, supporting both adherent and suspension processes with single-use technology. Targeted at gene therapy developers requiring clinical and commercial-grade lentiviral vectors.
  • Retroviral Vector CDMO Services Retroviral vector manufacturing services utilizing state-of-the-art facilities designed for aseptic manufacture, delivering larger batches with consistency and reliability. Designed for gene and cell therapy developers needing retroviral vector production.
  • Cell Therapy CDMO Services Cell therapy manufacturing services leveraging world-class partnerships to streamline production and advance cell therapies from trial through commercialization. Supports CAR-T and other cell therapy developers requiring integrated viral vector and cell therapy manufacturing.
  • Plasmids Manufacturing Plasmid design and manufacturing services, utilizing preferred partners' proven platforms or working with client-provided plasmids to meet unique requirements. Supports gene therapy developers across the manufacturing lifecycle.
  • Adeno-Associated Viral Vector CDMO Services AAV vector manufacturing services leveraging over a decade of experience with diverse platforms, processes, and analytics to advance programs from molecule to medicine. Targeted at gene therapy developers across preclinical, clinical, and commercial stages.
  • Propel: Discovery Discovery-stage support services designed to accelerate early development gene and cell therapy programs through Genezen's expertise and facilities. Targeted at developers in the earliest preclinical phases.
  • Analytical Development and Testing Services Comprehensive testing services including potency assays (biological titers, vector genome titers, TCID50), identity testing (VCN, insert stability, genome integrity by NGS), stability testing, purity testing, residual testing, and safety testing (RCL/RCR assays, sterility, endotoxin, mycoplasma).

Quantifiable outcome

  • Demonstrated functional titers of up to 1e7 TU/mL using Cytegrity™ system
  • +2 more outcomes

Companies that use Genezen

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Genezen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Genezen partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered secondary, core and minor.

  • SGSsecondaryStrategic or Co-development Partner · 1 June 2026Expanded partnership to strengthen support for foundation-funded gene therapy programs, providing comprehensive testing and quality services for rare disease therapies.
  • The Charlotte & Gwenyth Gray Foundation to Cure Batten DiseasesecondaryStrategic or Co-development Partner · 28 April 2026Manufacturing partnership to advance CLN6 gene therapy into Phase 1/2 clinical trial for Batten disease. Genezen supported rapid progression from proof of concept to GMP clinical supply using its viral vector platform and regulatory expertise, including direct FDA engagement.
  • Atsena TherapeuticscoreStrategic or Co-development Partner · 20 January 2026Strategic commercial manufacturing partnership for clinical development and commercial manufacturing of Atsena's AAV gene therapy pipeline, including ATSN-201 for X-linked retinoschisis targeting BLA filing in early 2028. Genezen leverages its viral vector manufacturing expertise to provide a streamlined and cost-efficient path to commercial manufacturing.
  • Atsena TherapeuticscoreStrategic or Co-development Partner · 20 January 2026Manufacturing partnership supporting Atsena's pivotal LIGHTHOUSE study for XLRS treatment and advancing programs toward regulatory approval and commercial launch.
  • Humane GenomicssecondaryStrategic or Co-development Partner · 12 November 2025Partnership to develop and manufacture HGI627, an oncolytic viral therapy targeting pediatric liver cancer. Collaboration involves process transfer and cGMP manufacturing using Humane Genomics' proprietary RNA virus platform.
  • Optieum BiotechnologiessecondaryStrategic or Co-development Partner · 25 May 2025Partnership to support cGMP manufacturing of groundbreaking CAR-T therapy for glioblastoma, leveraging Genezen's viral vector and cell therapy manufacturing capabilities.
  • Elly's TeamsecondaryStrategic or Co-development Partner · 13 May 2025Partnership for AAV9 gene replacement therapy targeting NEDAMSS (Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures). Genezen provided CMC expertise for development of analytical/ancillary studies to support IND submission, and Dr. Susan D'Costa joined the foundation's board.
  • Seattle Children's Research InstitutesecondaryStrategic or Co-development Partner · 6 March 2024Strategic manufacturing partnership for X-linked agammaglobulinemia (XLA) cell therapy program. Licensing of proven stable producer system for lentiviral vector production provides clients access to cutting-edge technology for stable and scalable high-titer clinical lentivirus production.
  • CSLcoreOEM/ Whitelabel/ Licensing Partner · 21 February 2024Licensing agreement for Cytegrity™ proprietary stable lentivirus production system from CSL. This next-generation technology offers remarkable efficiency, streamlined and cost-effective solution, seamless scalability, and reduced batch-to-batch variability with demonstrated functional titers up to 1e7 TU/mL.
  • Indiana UniversitysecondaryTechnology or Integration · 1 January 2015Research institution partnership providing access to the Indiana University Gene Therapy Testing Laboratory for clinical trial subject testing and release testing services, including RCL/RCR testing, PCR testing, insertion site analysis, and p24 ELISA.
  • Cincinnati Children's Hospital Medical CentersecondaryTechnology or Integration · 1 January 2015Research partnership with Cincinnati Children's Hospital Medical Center Translational Core Laboratory providing access to expertise in transducing hematopoietic progenitors, stem cells, T lymphocytes, and other immune cells for cell therapy manufacturing services.
  • Vanguard Clinical, Inc.minorStrategic or Co-development PartnerCollaboration with Vanguard Clinical for development support on CLN6 Batten disease program, with CEO Tiffany Sepp serving as Development Team Leader for the Gray Foundation.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Genezen competitors and assessment

Company assessment

Direct peers

  • Andelyn Biosciences: Columbus, OH-based viral vector CDMO offering lentiviral, AAV, and other viral vector manufacturing for gene therapy developers. Closely comparable to Genezen in multi-modality vector manufacturing, scale (similar facility footprint), and customer base (early- to mid-stage gene therapy developers).
  • Forge Biologics: Columbus, OH-based CDMO focused on AAV viral vector manufacturing and gene therapy development services. Direct competitor in the AAV CDMO space with overlapping customer segments (gene therapy biotechs from preclinical through commercial) and similar technology platform approach.
  • Viralgen (AskBio/Bayer): Spanish AAV CDMO owned by AskBio (acquired by Bayer), one of the largest dedicated viral vector manufacturers globally. Comparable to Genezen in AAV manufacturing focus, though at significantly larger scale and with European footprint advantage for global gene therapy sponsors.
  • Yposkesi (SK pharmteco): France-based lentiviral and AAV CDMO (formerly Yposkesi), now part of SK pharmteco. Highly comparable to Genezen in lentiviral vector manufacturing focus, multi-vector platform, and biotech client base; provides Genezen's main European-headquartered competition for viral vector programs.

Broad incumbents

  • Catalent (Novo Holdings): Large-scale global CDMO with viral vector manufacturing services for cell and gene therapies. Comparable as an incumbent competitor offering broader CDMO services (biologics fill-finish, oral dose forms) plus gene therapy vector production, competing with Genezen for larger gene therapy manufacturing RFPs.
  • Thermo Fisher Scientific (Patheon/Brammer Bio): Global life sciences services platform that acquired Brammer Bio (viral vector CDMO). Competes with Genezen across the viral vector CDMO space with significantly greater scale, integrated services, and balance sheet, particularly for late-stage and commercial gene therapy programs.
  • Lonza: Swiss global CDMO leader offering viral vector and cell therapy manufacturing services. Comparable to Genezen in viral vector and cell therapy manufacturing, but operating at substantially larger scale with broader biologics portfolio and global geographic footprint.
  • Resilience: Biomanufacturing technology company offering viral vector, cell therapy, and biologics manufacturing services. Compares to Genezen in viral vector CDMO services, with broader biomanufacturing portfolio and significant capital backing from public and private sources.

Emerging players

  • AavantiBio: AAV-focused gene therapy CDMO spun out from the University of Florida. Compares to Genezen in AAV manufacturing focus and gene therapy developer client base, though operating at earlier commercial scale and narrower single-modality platform.
  • Avectas (formerly Solentim): Cell engineering technology company supporting cell therapy developers including GMP manufacturing support. Adjacent peer to Genezen's cell therapy CDMO offering, with overlapping customer base in CAR-T and other cell therapy developers requiring lentiviral vector supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Genezen social profiles

Digital presence

Genezen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genezen leadership team

Management profile

Number of profiles

Profiles5 records

Genezen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genezen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genezen

What does Genezen do?

Genezen is a contract development and manufacturing organization (CDMO) providing end-to-end viral vector and cell therapy manufacturing services for gene therapy developers. Its offering spans lentiviral, retroviral, adeno-associated virus (AAV), plasmid, and cell therapy manufacturing supported by analytical development and testing services, delivered across two cGMP-compliant facilities in Fishers, Indiana and Lexington, Massachusetts.

Is Genezen a public or private company?

Genezen is a private company. It is classified as private equity controlled and is currently operating.

When was Genezen founded?

Genezen was founded in 2014. It employs 251 to 500 people.

Where is Genezen based?

Genezen is headquartered in Lexington, United States, in the North America region.

How does Genezen make money?

One revenue line is on record: CDMO Manufacturing Services.

Who are Genezen's main competitors?

Direct peers on record are Andelyn Biosciences, Forge Biologics, Viralgen (AskBio/Bayer) and Yposkesi (SK pharmteco). Broad incumbents are Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon/Brammer Bio), Lonza and Resilience. Emerging players are AavantiBio and Avectas (formerly Solentim).

Does Genezen have an API?

No public API is recorded for Genezen.

What industry is Genezen in?

Genezen's product category is Viral Vector and Cell Therapy Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGenezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human TrialGenezen and Galibra Neuroscience announced a partnership to advance Galibra's GAL005 AAV gene therapy for SSADH deficiency, with Genezen producing material for IND-enabling studies and a Phase 1 trial. The therapy restored survival in 100% of treated mice in preclinical studies, and the program holds FDA Orphan Drug and Rare Pediatric Disease designations.PR NewswireGenezen and InterAct Therapeutics Partner to Advance AAV8-based Gene Therapy for Liver-Dominant Metastatic Breast CancerGenezen and InterAct Therapeutics announced a manufacturing partnership to advance IAT-S2, an AAV8-based gene therapy targeting liver metastases in breast cancer. The therapy aims to modulate the liver microenvironment, with preclinical studies showing near elimination of liver metastases in mice. Genezen will support IND-enabling studies and Phase 1 trial production.PR NewswireGenezen Partners with Nevena Lešević and University of Missouri to Advance Personalized AAV9 Gene Therapy for Her Son with Ultra-Rare ARCA2Genezen partnered with Nevena Lešević and the University of Missouri to manufacture an AAV9 gene therapy for an N-of-1 clinical trial for her son Kosta, who has ultra-rare ARCA2 disorder. The therapy targets the PMPCA gene mutation, with no established treatment. The collaboration aims to accelerate manufacturing for the trial.ContractpharmaGenezen to Offer Access to 4basebio Synthetic DNA Platform for Viral VectorsGenezen is offering drug developers access to 4basebio's synthetic DNA platform for viral vector applications in an expanded non-exclusive collaboration. The hpDNA template requires about 30% less DNA mass and transfection reagent than plasmid DNA, potentially shortening production timelines. The companies say this will help developers move more efficiently from sequence to clinical programs.MarketScreener4basebio shares jump on new marketing tie-up with US-based GenezenNo content on the titled marketing tie-up with Genezen is present. The body is a company profile and stock data for 4basebio, describing its synthetic DNA platform and TruePrime technology, with no mention of the tie-up.AInvestThe Gene Therapy Boom Needs Better DNA. This Company Makes It — But Hasn't Proven It Yet.Cambridge-based 4basebio announced on August 26, 2026 a non-exclusive marketing and commercial agreement with viral vector CDMO Genezen to sell its cell-free hpDNA template, replacing bacterial plasmid production in gene therapy. The company reported 2025 revenue of £1.7 million, a 53% gross margin, £16.9 million net loss and £17.8 million cash, with roughly 12 months of runway.Gurufocus4basebio and Genezen Enter into Strategic Collaboration to Advan4basebio PLC and Genezen announced on Aug. 26, 2026 an expanded, non-exclusive collaboration giving drug developers access to 4basebio's Research Use Only, High-Quality and GMP-grade hpDNA synthetic DNA for viral vector applications. 4basebio's enzymatic cell-free process reportedly uses about 30% less DNA mass and transfection reagent than plasmid DNA, with shorter production timelines. Financial terms were not disclosed.Aijourn4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing4basebio PLC and Genezen announced an expanded, non-exclusive collaboration on Aug. 26, 2026, giving drug developers access to 4basebio's Research Use Only, high-quality and GMP-grade hpDNA synthetic DNA for viral vector applications. 4basebio's cell-free process reportedly uses about 30% less DNA mass and transfection reagent than plasmid DNA, with shorter production timelines. Financial terms were not disclosed.PR Newswire4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing4basebio PLC and Genezen announced on Aug. 26, 2026 an expanded, non-exclusive collaboration giving drug developers access to 4basebio's Research Use Only, High-Quality and GMP-grade hpDNA synthetic DNA for viral vector applications. 4basebio's enzymatic cell-free process reportedly uses about 30% less DNA mass and transfection reagent than plasmid DNA, with shorter production timelines. Financial terms were not disclosed.Investegate4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing4basebio PLC and Genezen announced on 26 August 2026 an expanded, non-exclusive collaboration giving drug developers access to 4basebio's hpDNA synthetic DNA for viral vector manufacturing. 4basebio's cell-free process reportedly uses about 30% less DNA mass and transfection reagent than plasmid DNA while achieving comparable titers. Financial terms were not disclosed.